IBA SA : IBA signs new Proteus®ONE binding term sheet with Proton Partners International
28 Juin 2016 - 7:00AM
IBA signs new
Proteus®ONE
binding term sheet with Proton Partners International
Louvain-La-Neuve,
Belgium, 28 June 2016 - IBA (Ion Beam Applications S.A.,
EURONEXT), the world's leading provider of proton therapy solutions
for the treatment of cancer, today announces it has signed a new
binding term sheet, containing a significant and immediate
down-payment, with Proton Partners International (PPI), to install
a Proteus®ONE* compact proton therapy solution. This latest Proteus®ONE purchase is part of PPI's strategy to expand its
proton therapy network internationally. The location of this center
will be disclosed at a later stage.
The term sheet covers delivery of
the Proteus®ONE equipment, including Pencil Beam Scanning (PBS) and
Cone Beam CT (CBCT) capabilities making it the only compact
solution ready for Adaptive Treatment. The term sheet also includes
a maintenance agreement. The typical end-user price for a Proteus®ONE system with a maintenance contract is between EUR
35 and 40 million and it is expected that the center will be
treating patients in 2018.
This center is the fourth to be
built for PPI and will be the 14th installation
of IBA's compact single-room proton therapy solution globally. IBA
has already sold 42 PT centers worldwide, with this project being
the latest to be signed as a result of the framework agreement with
Philips that has been in place since September 2014, demonstrating
the benefit of this relationship in bringing new international
contracts to fruition.
Olivier Legrain,
Chief Executive Officer of IBA, commented: "We are delighted
that IBA has been selected by PPI to build another new Proteus®ONE. PPI's
choice of IBA and our compact solution once again, not only
strengthens our world-leading position in proton therapy, but also
demonstrates the increasing demand for this cutting edge treatment
modality. At present, proton therapy represents only 1% of all
radiotherapy treatments, however, studies estimate that more than
17% of patients treated by radiotherapy would benefit from being
treated with proton therapy."
Mike Moran, Chief
Executive Officer of Proton Partners International Limited,
added: "The professional support and responsiveness that IBA
has demonstrated throughout our collaborations has resulted in the
signing of a new agreement with them. Cancer incidence is rising
dramatically, globally, and more innovation is needed to deal with
this disease. Our strategy of building a strong international
network of proton therapy centers will guarantee high quality
treatment throughout our network, enabling ever more patients to
benefit from cutting-edge proton therapy."
***ENDS***
About
Proteus®ONE
Proteus®ONE is the
compact intensity modulated proton therapy (IMPT) solution from
IBA. It benefits from the latest technologies developed with
renowned clinical institutions. Proteus®ONE is smaller, more
affordable, easier to install and to operate. It is ultimately
easier to finance, making this advanced radiation therapy modality
available to more institutions and patients worldwide.
Proteus®ONE makes
Proton Therapy easy.
* Proteus®ONE is the
brand name of a new configuration of the Proteus®235
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry.
Headquartered in Belgium and
employing about 1,300 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange
EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more
information can be found at: www.iba-worldwide.com
About Proton Partners
International Limited
Proton Partners International is a private limited company,
registered in Wales. The company was formed following discussions
between Professor Karol Sikora, former head of the World Health
Organisation's cancer programme, Professor Sir Chris Evans, the
leading life sciences entrepreneur, and Neil Woodford, founding
partner of Woodford Investment Management. Institutional and
private investors have committed to almost £100m equity finance in
the company.
Professor Gordon McVie, Senior
Consultant at the European Institute of Oncology, has been
appointed chairman, Professor Karol Sikora is Chief Medical Advisor
and one of the Founders, Mike Moran has been appointed as the Chief
Executive Officer.
For further information please
contact:
IBA
Jean-Marc Bothy
Chief Strategy Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com |
For media and investor
enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+1 917 322 2571
mcarey@RxIR.com
|
160627_IBA-PR-PPI-ProteusONE_EN-final
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#2023343
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024